Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pucotenlimab + lenvatinib + temozolomide
- Development stage
- Unknown
- Lead developer
- Shanghai Ninth People's Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination therapy integrates the humanized anti-PD-1 monoclonal antibody pucotenlimab with the multikinase inhibitor lenvatinib and the alkylating chemotherapy agent temozolomide. It is specifically being evaluated in a Phase II clinical trial (PLT-NAT-HNMM-II) led by Shanghai Ninth People's Hospital for the neoadjuvant and adjuvant treatment of resectable head and neck mucosal melanoma. Pucotenlimab works by inhibiting the PD-1/PD-L1 checkpoint, thereby reactivating the anti-tumor immune response. Lenvatinib targets multiple receptor tyrosine kinases, including VEGFR1-3 and FGFR1-4, to inhibit tumor angiogenesis and lymphangiogenesis. Temozolomide provides cytotoxic activity by alkylating DNA, leading to cell death. The triplet regimen aims to improve the prognosis of mucosal melanoma, which is typically resistant to conventional therapies.
- Brand names
- Puyouheng
- Other names
- Pucotenlimab + Lenvatinib + Temozolomide combination therapy
02
Targets
FGFR4 (Fibroblast growth factor receptor 4)PDCD1 (Programmed cell death protein 1 receptor)PDGFRA (Platelet-derived growth factor receptor alpha)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR3 (Fibroblast growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)DNAVEGFR3 (Vascular endothelial growth factor receptor 3)FGFR2 (Keratinocyte growth factor receptor)FGFR1 (Fibroblast growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)
Beyond the preview
Go deeper on pucotenlimab + lenvatinib + temozolomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pucotenlimab + lenvatinib + temozolomide.